Medtronic Earnings Call Transcripts
Fiscal Year 2026
-
Q4 and FY26 delivered strong revenue and EPS growth, with robust performance across key segments and significant progress in innovation and portfolio focus. FY27 guidance anticipates continued top-line acceleration, margin leverage, and ongoing investment despite tariff and macro headwinds.
-
Accelerated product launches, strategic M&A, and portfolio actions have driven strong momentum, with high single-digit EPS growth targeted for next year. CAS, renal denervation, and Altaviva are key growth drivers, while the MiniMed separation and selective commercialization of Hugo and Stealth Access platforms support long-term value creation.
-
Middle East exposure and oil price impacts are minimal, with logistics well managed and cost effects delayed by inventory cycles. The MiniMed separation is on track, supporting focused growth and higher margins, while CAS, Hugo, and Ardian franchises are set to drive accelerating growth and EPS leverage into 2027.
-
Q3 FY26 delivered 6% organic revenue growth, the highest in 10 quarters, with strong performance in CAS, CRM, and diabetes. Guidance for FY26 and FY27 remains robust, with high single-digit EPS growth expected, supported by innovation, new product launches, and disciplined capital allocation.
-
Medtronic is accelerating growth through four major product launches, increased R&D investment, and a focused portfolio strategy. Operational improvements and new board committees are driving margin expansion and faster decision-making, while tuck-in M&A and a diabetes spin-off support future innovation.
-
Q2 delivered strong revenue and EPS growth, driven by robust performance in cardiac ablation, Simplicity, and AltaViva launches. Full-year guidance for both revenue and EPS was raised, with accelerating momentum expected in the second half and into 2027.
-
Q1 FY26 saw 4.8% organic revenue growth and EPS above guidance, led by strong Cardiovascular and Diabetes performance. Full-year EPS guidance was raised, with accelerating growth expected from new product launches and business mix improvements. Governance enhancements and the Diabetes separation are set to drive further value creation.
Fiscal Year 2025
-
AltaViva addresses a large, underserved UUI market with a minimally invasive, long-lasting device offering immediate therapy and strong clinical outcomes. Aggressive consumer and physician engagement strategies are driving rapid adoption, with reimbursement and international expansion prioritized.
-
Growth is set to accelerate, with a focus on innovation, margin recovery, and high single-digit EPS growth. Operational improvements, targeted M&A, and enhanced board oversight support this strategy, while key pipeline products like CAS, Hugo, and RDN drive future value.
-
A unified supply chain and lean manufacturing have driven significant cost savings, with materials, labor, and logistics all contributing to improved margins. AI and automation are enhancing efficiency, while risk management and network optimization support resilience. Ongoing initiatives are expected to sustain 5% gross savings annually.
-
Leadership is driving data-centric capital allocation, operational efficiency, and aggressive investment in high-growth areas like CAS, RDN, and Hugo robotics. The diabetes business separation is on track, and board restructuring supports focused growth and margin expansion.
-
Management is focused on capitalizing on innovation, accelerating growth, and improving margins through operational discipline, targeted M&A, and increased R&D. Key growth drivers include new product launches in cardiac ablation, diabetes, and renal denervation, with a strong financial outlook for 2027.
-
The event highlighted a strategic focus on innovation-driven growth, portfolio optimization, and operational improvements, including the planned diabetes business separation. Key growth drivers include AI, robotics, and sensing technologies, with strong financial guidance and robust segment outlooks in cardiac ablation, renal denervation, and surgical robotics.
-
Q4 revenue grew 5.4% organically, with strong cardiovascular, neuromodulation, and diabetes growth. FY26 guidance calls for ~5% organic revenue and ~4% EPS growth, excluding tariffs, and the diabetes business will be separated via IPO and spinoff, expected to boost margins and EPS.
-
Q3 delivered 4.1% organic revenue growth and 6.9% EPS growth, led by strong performances in Cardiac Ablation, Neuromodulation, and Diabetes. Margin expansion, innovation, and robust international growth offset Medical Surgical headwinds, with guidance reaffirmed for FY25.
-
Momentum is accelerating across high-growth medtech segments, with major product launches in cardiac ablation, hypertension, neuromodulation, and diabetes. Operational efficiencies, disciplined capital allocation, and a robust innovation pipeline are expected to drive margin improvement and sustained earnings growth.
-
Reported 5% organic revenue growth and 8% EPS growth (constant currency), raising full-year guidance for both revenue and EPS. Strong performance in diabetes, neuroscience, and cardiovascular segments, with innovation and new product launches driving diversified growth.
-
Q1 delivered 5.3% organic revenue growth and adjusted EPS up 3% reported (8% constant currency), exceeding guidance. Strong innovation in diabetes, cardiac ablation, and neuromodulation drove results, prompting raised full-year revenue and EPS guidance.
Fiscal Year 2024
-
Strong innovation and digital transformation are driving growth in medtech, with healthy global procedure volumes and positive pricing trends. Key growth drivers include PFA for AFib, renal denervation, robotics, and partnerships in diabetes, while operational improvements and disciplined M&A support high single-digit EPS growth.
-
Innovation in high-growth areas and operational improvements are driving stable mid-single-digit revenue growth, with robotics, PFA, and next-gen products set to expand markets. Financial discipline and targeted capital allocation support a return to high single-digit EPS growth.